Read the latest insights from #GU26

From genomic predictors to real‑world combination strategies, experts highlight TP53 status as a potential marker of benefit, broad activity across disease features, and evolving mCRPC approaches

ow.ly/tuHe50Ypb0U

#ASCOGU #ASCOGU2026 #MedEd #MedSky

A new standard? Merck's Welireg combos deliver 1-2 punch to kidney cancer The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs from Merck’s Litespark clinical trial program for Welireg. | The treatment landscape for clear cell renal cell carcinoma could be due for a shake-up following dual breakthroughs from Merck’s Litespark clinical trial program for Welireg. But one critical factor could hinder these Welireg regimens from shifting from potential treatment options to the universal standard of care.

"LITESPARK-022 is the first adjuvant trial in kidney cancer to show a benefit for a combination versus a PD-1 agent alone." @danafarber.bsky.social’s Toni Choueiri, MD, featured in Fierce Pharma discussing kidney cancer research he presented at #ASCOGU.

➡️ bit.ly/3MTz0nq

Dr. Alicia Morgans of Dana-Farber Cancer Institute

Research at #ASCOGU: @danafarber.bsky.social’s Dr. Alicia Morgans provides insights from the ARANOTE trial during a poster session. The poster looks at the impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer.

Our Winter 2026 Genitourinary Oncology events are well underway, and the momentum continues. 👏
🎉 More sessions are happening tonight and tomorrow.

If you’re joining us, we look forward to continuing the conversation: https://bit.ly/49W3spJ

#ASCOGU #GenitourinaryOncology #CME #MedicalEducation

Xiao Wei, MD, of Dana-Farber Cancer Institute

At today's #ASCOGU poster session: @danafarbernews.bsky.social’s Xiao Wei, MD, presents on the effectiveness of systemic therapies after Lu-PSMA-617 treatment in patients with metastatic castration-resistant prostate cancer.

We're at #GU26! Stay informed on the latest research in #ProstateCancer and #BladderCancer with our live coverage from the event, plus keep an eye out for summary articles, free and on demand with Medthority 👀 #MedSky #ASCO #ASCOGU

ow.ly/HUNu50Ymiw3

Experts Preview Practice-Changing Data Ahead of 2026 ASCO GU | CURE Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

Expert analysis: Dr. Michael Serzan and Dr. Emre Yekedüz, both of @danafarbernews.bsky.social, preview the practice-changing data they expect this week at #ASCOGU.

Read more in @curetoday.bsky.social: bit.ly/46thzk5

ONCrg - What to Watch at ASCO GU
🚨 LIVE EVENT!
Register here: events.teams.microsoft.com/event/6cf5ce...

#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC

ONCrg is gearing up for ASCO GU 2026! If you’ll be attending and want to discuss how our reports can help you stay ahead of the curve in GU oncology, let’s connect. ONCrg Conference coverage: onc-rg.com/conferences/
#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC #OncologyCI #ONCrg #Genitourinary

We just launched our second GU cancer module. #BladderCancer is now live on Oncoscope-AI, joining our existing #ProstateCancer module.

If you treat GU cancers or work with teams preparing for #ASCOGU, request FREE access at the link in bio.

Read more here: bit.ly/4qb8gfP

Excellentes 1res Journées d’Actualités Normandes en Onco-Urologie – #JANOU2025 !
Toutes les nouveautés prostate, rein, vessie + grands changements 2025 (#CCAFU #ASCOGU).
Médecins, urologues, oncologues, radiothérapeutes réunis !
#OncoUrologie #Urologie #Oncologie #Normandie

Welche Highlights wurden auf dem #ASCO 2025 vorgestellt, medtoday fasst für Sie alle Highlights zusammen!
medtoday.de
#ASCOGU #Medizin #Forschung

Very proud of rising star fellow Aditi Gupta for her work on immune profiling in mUC patients receiving EV #ASCOGU @MSKCancerCenter #GU25

#ASCOGU: Lilly’s early bladder cancer data hint at safety edge over J&J’s Balversa Eli Lilly has shared first-in-human results for its selective FGFR3 inhibitor in a subset of bladder cancer patients, marking the start of a program that could eventually challenge Johnson & Johnson’s Balversa. Balversa is marketed ...

Thoughts on this? >> #ASCOGU: Lilly’s early bladder cancer data hint at safety
edge over J&J’s Balversa: Eli Lilly has shared first-in-human results for its selective FGFR3… >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare

Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with

ORR of 41%
DCR 90%
50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor

@MSKCancerCenter #ASCOGU #GU25

Excited to hear a review of the DV + PD-1 from our MSK Cancer Center colleague Scot Niglio #ASCOGU #GU25

Path Cr rate of 84.6% in HER2 3+

#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor data for Nectin-4 ADC Corbus Pharmaceuticals reported encouraging early-stage results for its Nectin-4 targeting ADC in various types of cancer, but a lack of response in certain patients caused shares to slide. The biotech’s CRB-701 is given once every ...

Thoughts on this? >> #ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor data
for Nectin-4 ADC: Corbus Pharmaceuticals reported encouraging early-stage results for its… >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #productmarketing #biotech

Great discussion of salvage options for local failure after prostate radiotherapy. Particularly consider surgery for seminal vesicle recurrence with potential low morbidity.

#ASCO #ASCOGU

#ASCOGU: Pfizer’s prostate cancer data leak shows promising results in early-stage study Clinical trial results from a Phase 1 study by Pfizer leaked days before a late-breaking presentation scheduled for Thursday, showing that the drugmaker’s prostate cancer candidate cut the risk of disease progression by around half ...

Thoughts on this? >> #ASCOGU: Pfizer’s prostate cancer data leak shows promising
results in early-stage study: Clinical trial results from a Phase 1 study by Pfizer leaked… >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #pharmaceutical #healthcare

🔥 #TestisCancer highlight from #ASCOGU!

📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma.

Important data for #GermCellTumors! What’s your take?

🚀 Key #UrothelialCancer abstracts from #ASCOGU!
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.

🔥 Exciting #ProstateCancer Abstracts from #ASCOGU:
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.